Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

PET-imaging of two Vartumabs (F8scFv and C9scFv) in patients with solid tumors – a Phase 0 basket trial Recruiting

2024-513827-18-00 Multiple solid tumors including: colorectal carcinoma ( 1 2024-11-29
The effect of [18F]F-FAPI PET-CT on management in patients with potentially resectable biliary tract cancers: prospective multicenter study … Recruiting

2023-507938-24-00 Cholangiocarcinoma 5 2024-11-29
Concomitant HPV vaccination and HPV screening for rapid elimination of HPV infection and cervical cancer in Sweden Recruiting

2024-518857-41-00 HPV infection and related diseases, such as cervical in 6 2024-11-29
Iberdomide combined with low-dose cyclophosphamide and dexamethasone: ICON study Recruiting

2023-508902-66-00 relapsed / refractory multiple myeloma 4 2024-11-28
LAG3 PET; ImmunoPET imaging with 89Zr-DFO-REGN3767 in patients with advanced solid cancer prior to and during treatment with cemiplimab with… Recruiting

2024-516795-15-00 Metastatic solid tumors, these may include but are not 4 2024-11-27
Prevention of thromboembolism during pancreatic cancer treatments - link to prognosis and relapse of the disease. Recruiting

2024-512475-12-01 We are investigating the efficacy and safety of enhance 6 2024-11-27
A Phase 2, open label, randomized study of neoadjuvant dostarlimab plus CAPEOX versus CAPEOX in participants with previously untreated T4N0 … Recruiting

2024-513441-36-00 MMRp/ MSS colon cancer 4 2024-11-27
A Phase 1 Study of BMS-986453 in Participants with Relapsed and/or Refractory Multiple Myeloma Recruiting

2023-506003-26-00 Relapsed and/or Refractory Multiple Myeloma 1 2024-11-27
Carboplatin + Paclitaxel + Cetuximab (PCC) after failure of first line Immune checkpoint inhibitor with or without chemotherapy in recurrent… Recruiting

2024-512297-96-01 Head and neck squamous cell carcinoma 4 2024-11-26
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting

2024-512279-10-00 Triple Negative Breast Cancer 5 2024-11-25
Detection of tumor tiSsue in pEritoneal metastases of coLorectal origin using a VEGF-targeted optical fluoresCent imaging tracer during diag… Recruiting

2024-517718-13-01 peritoneal metastases of colorectal origin 3 2024-11-25
Subcutaneous Tarlatamab in Subjects with Extensive Stage Small Cell Lung Cancer (DeLLphi-308) Recruiting

2024-511838-12-00 Extensive Stage Small Cell Lung Cancer (DeLLphi-308) 3 2024-11-22
Metronomic neoadjuvant capecitabine and cyclophosphamide in huge (PCI>28) Pseudomyxoma peritonei (PMP) patients candidates to cytoreductive … Recruiting

2024-514329-42-00 Pseudomyxoma peritonei patients with high tumor burden. 4 2024-11-22
A Study of ZL-1310 in Patients with Small Cell Lung Cancer to Find a Suitable Dose and to Test How Different Doses of ZL-1310 are Tolerated … Recruiting

2024-514446-36-00 Small Cell Lung Cancer 1 2024-11-21
HR-NBL2: High-risk neuroblastoma study 2.0 of SIOP-Europe- Neuroblastoma/SIOPEN: Randomised, international and multicentric phase 3 study t… Recruiting

2024-514917-36-00 Patients with High Risk Neuroblastoma 5 2024-11-21
An open-label, phase I/II multicenter clinical trial of NECVAX-NEO1 as add-on to first-line neoadjuvant anti-PD-1 monoclonal antibody therap… Recruiting

2024-512520-11-00 Triple negative breast cancer (TNBC) 9 2024-11-19
MEPENDAX: Phase I/II study of axitinib (Inlyta®) and oral metronomic etoposide for pediatric children and AYA with refractory/relapsing medu… Recruiting

2023-509585-38-00 Ependymoma 9 2024-11-19
A study to learn BAY 3498264 when given alone or together with sotorasib in participants who have advanced solid cancers with specific genet… Recruiting

2024-513300-34-00 Advanced solid tumors harboring KRAS G12C mutation 1 2024-11-18
Single-arm interventional study with ruxolitinib and AIEOP-BFM 2017 Poland or AIEOP-BFM 2017 standard of care chemotherapy in children with … Recruiting

2024-518316-39-00 Acute lymphoblastic leukemia 10 2024-11-18
A randomized, run-in, phase II study of nivolumab combined with ipilimumab and oral decitabine/cedazuridine (ASTX727) or nivolumab combined … Recruiting

2024-518891-29-00 MM and NSCLC patients resistant to anti-PD-1/PD-L1 ther 4 2024-11-18
Randomized Phase II, 2-arm Study of Immunomodulation with Atezolizumab concomitant with High Dose Radiation (SBRT) Versus SBRT Alone in Pati… Recruiting

2024-511313-38-00 Soft Tissue Sarcoma 4 2024-11-17
Assessment of short immunotherapy after radical surgery of high-risk malignant melanoma Recruiting

2023-509994-22-00 cutaneous malignant melanoma 5 2024-11-15
A first-in-human study of PARP1 selective inhibitor, IMP1734, in patients with advanced solid tumors. Recruiting

2023-509230-19-00 Advance solid tumors 7 2024-11-14
MK-1084 with Pembrolizumab in 1L Locally Advanced or Metastatic NSCLC With KRAS G12C Mutations and PD-L1 ≥50% Recruiting

2023-507776-42-00 Non-small cell lung cancer 5 2024-11-14